22m
Wellgistics Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet(TM)
GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301Proprietary Forzet formulation provides ...
The two companies announced today that Hims & Hers will now be able to sell Novo Nordisk's injectable and oral semaglutide products, sold respectively as Ozempic for type 2 diabetes and Wegovy for ...
52m
Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration
Hims & Hers Health has agreed to stop selling compound versions of Novo Nordisk's Wegovy and other weight-loss drugs, ending for now a patent lawsuit.
Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.
22mon MSN
Hims & Hers stock soars. Its weight-loss drug battle with Novo Nordisk takes a surprising twist.
Novo Nordisk has agreed to sell its weight-loss injectables and its Wegovy pill on Hims’ platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results